Literature DB >> 9408861

Bayesian nonparametric population models: formulation and comparison with likelihood approaches.

J Wakefield1, S Walker.   

Abstract

Population approaches to modeling pharmacokinetic and/or pharmacodynamic data attempt to separate the variability in observed data into within- and between-individual components. This is most naturally achieved via a multistage model. At the first stage of the model the data of a particular individual is modeled with each individual having his own set of parameters. At the second stage these individual parameters are assumed to have arisen from some unknown population distribution which we shall denote F. The importance of the choice of second stage distribution has led to a number of flexible approaches to the modeling of F. A nonparametric maximum likelihood estimate of F was suggested by Mallet whereas Davidian and Gallant proposed a semiparametric maximum likelihood approach where the maximum likelihood estimate is obtained over a smooth class of distributions. Previous Bayesian work has concentrated largely on F being assigned to a parametric family, typically the normal or Student's t. We describe a Bayesian nonparametric approach using the Dirichlet process. We use Markov chain Monte Carlo simulation to implement the procedure. We discuss each procedure and compare our approach with those of Mallet and Davidian and Gallant, using simulated data for a pharmacodynamic dose-response model.

Mesh:

Year:  1997        PMID: 9408861     DOI: 10.1023/a:1025736230707

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  4 in total

1.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  A population approach to initial dose selection.

Authors:  J Wakefield; S Walker
Journal:  Stat Med       Date:  1997-05-30       Impact factor: 2.373

3.  Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine.

Authors:  A Mallet; F Mentré; J L Steimer; F Lokiec
Journal:  J Pharmacokinet Biopharm       Date:  1988-06

4.  A simulation study comparing designs for dose ranging.

Authors:  L B Sheiner; Y Hashimoto; S L Beal
Journal:  Stat Med       Date:  1991-03       Impact factor: 2.373

  4 in total
  6 in total

Review 1.  Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science.

Authors:  Goonaseelan Colin Pillai; France Mentré; Jean-Louis Steimer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.745

2.  Sequential updating of a new dynamic pharmacokinetic model for caffeine in premature neonates.

Authors:  Sandrine Micallef; Billy Amzal; Véronique Bach; Karen Chardon; Pierre Tourneux; Frédéric Y Bois
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  Eur J Clin Pharmacol       Date:  2008-05-16       Impact factor: 2.953

4.  Nonlinear Random Effects Mixture Models: Maximum Likelihood Estimation via the EM Algorithm.

Authors:  Xiaoning Wang; Alan Schumitzky; David Z D'Argenio
Journal:  Comput Stat Data Anal       Date:  2007-08-15       Impact factor: 1.681

5.  Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.

Authors:  Tatiana Tatarinova; Michael Neely; Jay Bartroff; Michael van Guilder; Walter Yamada; David Bayard; Roger Jelliffe; Robert Leary; Alyona Chubatiuk; Alan Schumitzky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-13       Impact factor: 2.745

6.  Population Pharmacokinetic/Pharmacodyanamic Mixture Models via Maximum a Posteriori Estimation.

Authors:  Xiaoning Wang; Alan Schumitzky; David Z D'Argenio
Journal:  Comput Stat Data Anal       Date:  2009-10-01       Impact factor: 1.681

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.